| Metric | Q1'26 | Q2'26 | Change |
|---|---|---|---|
| Adjusted Operating EPS | $2.74 (Q1'26) | $2.55 (Q2'26, +$0.64 YoY) | -$0.19 QoQ, but +$0.64 YoY |
| GAAP EPS | $4.49 (Q1'26) | $1.42 (Q2'26) | -$3.07 QoQ swing, mark-to-market driven |
| FY2026 Guidance Range | $11.00-$12.00/share, affirmed | $11.50-$12.50/share, raised | +$0.50 midpoint raise |
| Nuclear Capacity Factor | 92.3% (Q1'26) | 93% (Q2'26) | +70bps despite heavier outage schedule |
| Combined Cycle/Cogen Capacity Factor | 47.1% disclosed | Not disclosed this quarter | Metric dropped from disclosure |
| Illinois ZEC Bank Credits Recognized | Lower ZEC pricing across state programs flagged as a Q1 headwind, no specific Q2 comp given | $85M vs $200M prior-year Q2 | -57.5% YoY timing swing, flagged by mgmt as non-impactful to FY |
| Share Repurchases (cumulative since March outlook) | $335M (Q1 alone) | $2.2B cumulative (4 months) | 6.6x acceleration |
| Remaining Buyback Authorization | $5B authorization contemplated at outset | $2.8B explicit | ~40% of $5B authorization already deployed |
| PJM Interconnection Queue - New Capacity Submitted | ~5,000MW, 'probably a good bit more' with Calpine | No updated MW figure given; deflected to 'confidential' bilateral process | Metric replaced by non-answer |
| 2029 Capital Allocation Sensitivity (buyback lever) | '$0.50 plus' upside, no floor | Floor $0.20/share, upside >$0.75/share | Floor added, range widened |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.